Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Infratentorial Neoplasms / genetics"'
Autor:
André O. von Bueren, Martin Mynarek, Stefan Rutkowski, Ludger Klein-Hitpass, Inken Wohlers, Torsten Pietsch, Stephanie T Jünger, Sven Rahmann, Beate Timmermann, Natalia Velez-Char, Monika Warmuth-Metz, Katja von Hoff, Rolf-Dieter Kortmann, Evelyn Dörner, Anja zur Mühlen
Publikováno v:
Acta Neuropathologica Communications, Vol 7, Iss 1, Pp 1-12 (2019)
Acta Neuropathologica Communications
Acta neuropathologica communications, Vol. 7, No 1 (2019) P. 181
Acta Neuropathologica Communications
Acta neuropathologica communications, Vol. 7, No 1 (2019) P. 181
Introduction Risk stratification of children with ependymomas of the posterior fossa in current therapeutic protocols is mainly based on clinical criteria. We aimed to identify independent outcome predictors for this disease entity by a systematic in
Autor:
Martin Mynarek, Stephanie T Jünger, Evelyn Dörner, Stefan Rutkowski, Felipe Andreiuolo, Anja zur Mühlen, André O. von Bueren, Torsten Pietsch
Publikováno v:
Child's nervous system, Vol. 36, No 11 (2020) pp. 2693-2700
Child's Nervous System
Child's Nervous System
Introduction Young age is an adverse prognostic factor in children with ependymomas. Treatment of these infants is challenging since beneficial therapeutic options are limited. As ependymomas are considered a biologically heterogeneous group, we aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23b4645cbc78ae6e992b919a1fe7d95b
https://archive-ouverte.unige.ch/unige:157307
https://archive-ouverte.unige.ch/unige:157307
Autor:
Manfred Westphal, Markus Glatzel, Carsten Friedrich, Christian Bernreuther, Ronald Simon, André O. von Bueren, Diego Sepulveda-Falla, Larissa Kolevatova, Leander van den Boom, Tobias Grob
Publikováno v:
Child's Nervous System, Vol. 32, No 2 (2016) pp. 281-90
The aim of this study was to investigate the epidermal growth factor receptor (EGFR) status in ependymoma specimens, as there is a need for new prognostic and druggable targets in this disease. Ependymomas (WHO grade II, n = 40; WHO grade III, n = 15